Efficacy Comparison of Warfarin Versus Rivaroxaban CVT

Comparing Treatment Outcomes in CVT Patients Who Treated With Warfarin and Rivaroxaban in Isfahan, Iran

Status

UNKNOWN

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03747081

Enrollment

Registered

2018-11-20

Start date

2018-09-01

Completion date

2020-05-01

Last updated

2018-11-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebral Venous Thrombosis

Brief summary

With regard to Cerebral Venous Thrombosis (CVT) importance as a life threatening disease, specific care is necessary, Known anti-coagulants have limitations.Vitamin K antagonists such as Warfarin, require laboratory monitoring and exact administration starting and maintenance dose. although Rivaroxaban(selective and direct Xa factor antagonist ) has no monitoring and no drug interaction. This study aim to focus on efficacy of Warfarin versus Rivaroxaban.

Interventions

DRUGRivaroxaban

Rivaroxaban will administrate to patient with CVT. In first day, enoxaparin is injected to patients and the next day, patients will receive Rivaroxaban and enoxaparin discontinue. Then, patients receive Rivaroxaban for 3 months daily.

DRUGWarfarin

Warfarin as a antocoagolant drug will administrate to patient with CVT. In first day, Warfarin plus enoxaparin until adjusting INR index to 2-3. Then, patients receive warfarin for 3 months daily.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

IInclusion Criteria: * Patients of both gender * Age 18 years and higher * proven CVT on neuro imaging ( MRI-MRV)

Exclusion criteria

* Patients suffering from renal failure(GFR\<30) Patients * Patients with contraindications for oral anticoagulation * Patient who having pregnancy * Uncooperative patient for completing the course of treatment

Design outcomes

Primary

Measure	Time frame	Description
Modified Rankin Scale	3 months	based on disability grade(0-6). 0 indicate patients have no disability and the worst score is 6.

Secondary

Measure	Time frame	Description
hemorrhagic rate	3 months	based on repeat MRI
Stroke	3 months	based on MRI

Countries

Iran

Contacts

Primary ContactMohammad Javad Farajpour Khanaposhtani, MD

mjf.khp@gmail.com00989193967294

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026